Armour Pharmaceutical Company Limited

St. Leonards House, St. Leonards Road, Eastbourne, Sussex BN21 3YG
Telephone: Eastbourne (0323) 21422 Telex: GRO-C

G0000001/1

RBC/EB

June 4, 1985

Dr. F. E. Preston,
Consultant Haematologist,
Sheffield Regional Haemophilia Centre,
Royal Hallamshire Hospital,
Glossop Road,
Sheffield,
YORKSHIRE,
S10 2JF.

Dear Dr. Preston;

RE: HEAT TREATED FACTORATE BATCH NO. Y69402

Further to Mr. Bishop's letter of 10th May, we have been advised by the Department of Health that they would be very interested if all patients who have received this batch of material could be followed up for HTLV-III antibody conversion and/or any clinical or haematological signs of AIDS or pre-AIDS symptomology.

They would also like to know the numbers of patients who received this particular batch of material.

It would be extremely helpful if you could assist in this matter in the following way:

(i) Provide the number of patients who received Factorate batch Y69402, the dose and the number of separate occasions that the product was administered to individual patients.

(ii) If known, the HTLV-III antibody status of these patients prior to receiving Y69402.

(iii) The patient's clinical condition and immunological status prior to receiving Y69402.

(iv) The patient's current HTLV-III antibody status, and clinical condition, T4 T8 lymphocyte ratio, etc., and then a follow-up at approximately six month intervals for two years.

All information will be treated in the strictest confidence and it is not necessary to identify patients by name.

Cont'd. .....

June 4, 1985

I realise that this request imposes an additional burden on your unit, but it is an unusual opportunity to assess the effectiveness of heat treatment in rendering a batch of Factor VIII safe which was known to contain plasma from a donor who has developed AIDS.

Your kind assistance would be much appreciated. If we can help in any way, please let me know. We are making a similar request to the other centres who received the batch in question.

Kind regards,

Yours sincerely,

GRO-C

R. B. Christie,
DIRECTOR OF CLINICAL SCIENCES